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Introduction
Solid tumors are often relatively chemo-and radiation-resistant, due in part to the presence of hypoxia (1) . Inorganic arsenic trioxide (ATO) is an established chemotherapy drug for treatment of acute promyelocytic leukemia (APL) that inhibits the APL-specific oncoprotein, AML-RXRĮ. We and others have previously reported that ATO has cytotoxic and radiosensitizing effects in solid tumor models, at least partially attributable to the induction of oxidative stress (2) (3) (4) (5) . Unfortunately, ATO was less efficacious in clinical trials of solid tumors than leukemia, and has dose-related risks of cardiac and hepatic toxicity (6) . Recently, a number of organic arsenics with anti-cancer activities have been developed (7) (8) (9) (10) (11) . Their mechanisms of action are different from those of ATO, and include effects on tumor angiogenesis (11) , metabolism (12) , and cell signaling (NF-kappaB) (9) . As a result, unlike ATO, these organic arsenicals do not depend on AML-RARĮ inhibition for their anti-leukemic activities (8, 13, 14) , and may be useful for treatment of other cancers including solid tumors.
Darinaparsin (DPS) is an organic arsenical with potent activity against leukemia and multiple myeloma, with approximately 3-10 times greater cytotoxicity than ATO in vitro (15) . Remarkably, much higher doses of DPS can be safely used in animal models with significantly less systemic toxicity than ATO (16) . These favorable toxicity profiles have been confirmed in phase I and II clinical trials (17, 18) . Like other organic arsenics, DPS does not induce differentiation of APL cells, and does not cause PML-RARĮ degradation and rearrangement of PML nuclear bodies (19) . Neither myeloma nor APL ATO-resistant cell lines are resistant to DPS (20) . In addition, DPS has been reported to have in vitro cytotoxic activity against a variety of solid tumor cell lines (19) . These findings suggest that DPS may have different mechanisms of action than ATO, and may be an effective anti-solid tumor agent. Since hypoxia is an important determinant of chemo-and radioresistance, we assessed the in vitro activities of DPS under both hypoxia and normoxia, The in vivo model of primary prostate cancer using tissue slice grafts (TSGs) has been previously described (21) . The TSGs maintain the normal and cancer tissue histology as evidenced by immunohistochemical staining, and respond to androgen ablation. Briefly, a prostate cancer specimen (Gleason score 4+3) obtained from radical prostatectomy was precision-cut into TSGs of 5-mm diameter and 300-ȝm thickness, which were subsequently implanted under the renal capsules of male RAG2 -/-ȖC -/-mice ( Fig 1D) .
After one month of establishment, mice bearing consecutive TSGs were paired and treated with DPS (100 mg/kg, IP, TIW) or saline as a control. The TSGs were recovered,
Research. For the study of the DPS effect in combination with radiation on normal intestine, we used an established microcolony assay that measured the intestinal stem cell survival (as the number of crypts /cross-section) after radiation (22) . Technology, Beverly, MA) antibodies, and then with goat anti-rabbit (1:2,000, Cell Signaling) for 1 hour at room temperature.
RNA isolation and microarray analysis. Total RNA was isolated using TRIzol (Invitrogen) and purified using a 'RNeasy MinElute Kit' (Qiagen, Valencia, CA). The microarray hybridization was conducted by Stanford Functional Genomics Facility using array chips (SurePrint G3 Human GE 8x60k, Agilent Technologies, Santa Clara, CA). A Universal Human Reference RNA (Agilent) was used as the control for each sample. Other assays. Intracellular total GSH concentrations were determined using the GSH reductase recycling assay (23) and normalized with protein concentration. DNA damage was assessed using the neutral comet assay (24) . One hundred cells were scored for each sample and the data were expressed as the mean moment (tail length * intensity of DNA in the tail ± SE). Mitochondrial membrane potential (MMP) was measured by JC-1 (Invitrogen, 10 ȝg/mL, 1 hr) staining and flow cytometry (25) . Senescence was measured using SA (senescence associated)-ȕ-Gal-staining (26) , and expressed as the ratio of positive stained cells to total number of cells.
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on July Fig 1A) . The IC 50 s were similar under either normoxia or hypoxia, indicating that the effect of DPS on cell proliferation was O 2 -independent. In comparison, IC 50 s of ATO were ~2-to 6-fold higher than DPS, with hypoxic IC 50 s generally higher than corresponding normoxic IC 50 s, indicating that ATO activity against these cell lines was less potent than DPS and O 2 -dependent to a certain extent. In clonogenic assays which assess the ability of individual cells to proliferate and give rise to colonies, the IC 50 /4hr of DPS was ~1 -3 ȝM for the cell lines studied under both normoxia and hypoxia (Suppl Table 2 ).
Next the effect of DPS on tumor growth in vivo was determined using mouse models with established HI-LAPC-4 and PANC-1 subcutaneous xenograft tumors. The mice were injected with DPS intraperitoneally 3 times/wk with a dose of 100 mg/kg for 4 wks.
Toxicology studies, including blood chemistry panels, did not indicate any systemic toxicity with similar doses except for changes in physical activity and body weight (16) (Suppl Fig 1A and Suppl Table 3 ). In pharmacokinetic studies with human subjects (18), this regimen achieved blood arsenic concentrations (C max , ~10 ȝM) above the IC 50 s observed in our in vitro studies (Fig 1A and Suppl Table 2 ). In both HI-LAPC-4 and PANC-1 tumor models, DPS significantly inhibited tumor growth (P < 0.0001) (Fig 1 B1 and B2), with the average tumor volume doubling time increased from 4 to 13 days in HI-LAPC-4 tumors (P < 0.001), and 4 to 7 days in PANC-1 tumors (P < 0.001).
Finally, the activity of DPS in a novel and clinically relevant tumor slice graft (TSG) model of primary prostate cancer was tested. Mice that received consecutive TSGs (Gleason score 4+3) were paired and treated with DPS (100 mg/kg, IP, 3 times/week for 4 weeks) or saline as a control (Fig 1C) . After recovery, the TSGs were fixed and serially sectioned. The presence of cancer in each section was evaluated by AMACR staining, and AMACR-positive areas were imaged and quantitated. The total areas of the TSG sections from DPS-and saline-treated mice that were evaluated were similar (data not shown). In three of the four TSG pairs, DPS decreased the total tumor area to less than 50% of the control. Although the difference (P = 0.139 by paired t-test) was not statistically significant, possibly due to the small sample size of this pilot study, overall the findings suggest DPS-induced cytotoxicity in primary prostate cancer as well as 
with a clinically relevant fractionated radiation regimen was also tested. In this regimen, DPS (100 mg/kg, IP) was administered 4 hr before radiation (2 Gy/day) for 3 consecutive days using the HI-LAPC-4 tumor model. A significant delay of tumor volume doubling time was observed from 7 days with radiation alone and 6 days with DPS alone to 19 days for the combined treatment of radiation and DPS (Fig 2B3, P < 0.0001) .
DPS did not radiosensitize normal radiosensitive tissues. The body weight loss observed in the radiosensitization regimen, either by DPS alone or in combination with radiation, was minimal (< 5%, Suppl Fig 1A) . Serial complete blood counts (CBCs, indicators of bone marrow function) were obtained following total body radiation (3.5 Gy) with or without DPS treatment (100 mg/kg, 4 hr, IP). As expected, the white blood cells (WBC), platelet, red blood cells (RBC), and hemoglobin (HGB) significantly decreased after the radiation and recovered over time. DPS did not affect these CBC changes ( Fig   3A) . Using the established intestinal microcolony assay, we observed a significant decrease in viable duodenal crypt cells following radiation. However, to our surprise, DPS treatment significantly enhanced the survival of crypt cells following irradiation ( Fig   3B) . In comparison to saline-treated controls, the DPS-treated mice had nearly 10 times more viable crypts at 3.5 days after radiation (10-12 Gy). Similar results were observed in the jejunum and ileum (data not shown). The data therefore indicate that DPS does not sensitize, and may even protect, normal radiosensitive tissues to radiation.
DPS induced apoptosis and senescence but not autophagy in HI-LAPC-4 cells.
DPS caused HI-LAPC-4 cell death in a time (24 and 48 hr)-dependent manner, as demonstrated by Trypan Blue exclusion assay (Fig 4A) . We therefore assessed the modes of cell death after DPS treatment. After 24 hrs of DPS treatment (10 ȝM, 8 hr), there was a significant increase in caspase-3 cleavage (Fig 4B) and annexin V externalization (Fig 4C) under both normoxia and hypoxia, indicating cell death by apoptosis. Importantly, after 24 hr incubation in hypoxia, DPS was more cytotoxic to HI- LAPC-4 cells, which is in contrast to equivalent effects of DPS in normoxia and hypoxia after only 4 hr incubation (Fig 1A) . In addition, a small proportion of cells that survived DPS treatment had morphologic features of senescence with increased expression of SA-ȕ-galactosidase (Fig 4D) . Finally, morphological (vacuole formation) and LC-3 activation (an autophagy marker) ( Suppl Fig 2) suggested autophagy was not involved in DPS-induced cell death. A cell cycle analysis was also conducted and revealed no apparent cell cycle arrest after 24 hr of DPS treatment ( Suppl Fig 3) .
DPS cytotoxicity was independent of ROS generation and DNA or mitochondria damage. Since DPS-induced cytotoxicity in hematologic cancer cell lines is mediated by ROS generation, with subsequent mitochondrial damage (19), we determine the effect of DPS on cellular ROS in solid tumor cell lines. Using the fluorescent probe CM-H2DCFDA, we observed a dose-dependent increase of cellular ROS in DPS-treated HI-LAPC-4 cells under normoxia but not hypoxia (Fig 5A) . In addition, DPS depleted cellular antioxidant GSH in normoxia, but not hypoxia (Fig 5B) . Since ROS generation disrupts normal protein folding in the endoplasmic reticulum (ER), and subsequently induces ER stress and unfolded protein response (UPR) (27) , the level of ER stress following DPS treatment was assessed using an established luciferase reporter model for UPRactivated transcription factors XBP-1 or ATF-4 (28). As expected, DPS caused a dosedependent activation of XBP-1 and ATF-4 under normoxia, but not under hypoxia ( Fig   5C) . Finally, in HI-LAPC-4 cells under normoxia (but not hypoxia), there was a moderate increase of DNA damage (Comet assay, Fig 5D) and DNA damage response (ȖH2AX, Fig 5E) following DPS treatment. However, when cells were pretreated with DPS for 4 hours and then irradiated, there was no synergistic increase in ȖH2AX at either 0.5 or 12.5 hours after irradiation (Suppl Fig 4) . In summary, the data above demonstrate that DPS did not induce oxidative stress under hypoxia, indicating the existence of ROSindependent mechanisms of DPS cytotoxicity. While DPS significantly decreased (28%, P < 0.01) mitochondrial membrane potential (MMP) in an APL cell line, HL-60 (19, Suppl Fig 5A) , it did not significantly affect the MMP in the five solid tumor cell lines tested, with the exception of HI-LAPC-4 under normoxia (31%, P < 0.05). In addition, there was no increase of mitochondrial ROS under either normoxia or hypoxia (Suppl Fig 5B) , indicating that ROS generation did not cause detectable mitochondrial damage in the majority of the solid tumor cell lines studied, and is not a primary mechanism of DPS cytotoxicity in the these cells.
The anti-tumor effect of DPS was associated with inhibition of oncogenic signaling pathways. The lack of immediate DNA and mitochondrial damage suggested that DPS-induced cell death was mediated by signaling events. In addition, cycloheximide (CHX, a translation inhibitor) significantly decreased DPS cytotoxicity under both normoxia and hypoxia (P < 0.0001 for the interaction of CHX and DPS by 2-way ANOVA, Suppl Fig 6) , indicating that DPS activity required de novo protein expression. Next, DPS effects on Hypoxia-induced factor IĮ (HIF1Į) and c-Jun NH2-terminal kinase (JNK) were studied because of their roles as a regulator of cell survival and radiosensitivity under hypoxia (1) and a mediator of DPS cytotoxicity in leukemia cells (15) , respectively. The data indicate that neither factor likely plays a significant role in DPS-mediated cytotoxicity in solid tumor cells under hypoxia ( Suppl Fig 7-8 ).
Gene expression profiling was performed with HI-LAPC-4 cells after 4 and 8 hrs incubation with DPS or ATO at the concentrations of IC 50 /4hr (Fig 1A) under normoxia. Table 4A 
and B). An Ingenuity
Pathway analysis demonstrated that DPS affected multiple biological processes and pathways that involve cancer, inflammation, and apoptosis (Suppl Table 4C ). Transcription Factor Target Enrichment Analysis identified transcription factors whose target gene expression was significantly affected by DPS (DPS/CON) and ATO (ATO/CON), many of which were associated with oncogene regulated pathways (Suppl Table 4D ).
To further assess the effect of DPS on oncogenic pathways, we interrogated the microarray data against established oncogene-dependent gene expression signatures (Fig 6) .
Specifically, DPS significantly decreased the expression of genes that were upregulated by RAS, and increased the expression of genes that were down-regulated by MYC. In contrast, ATO only affected AR signaling. Next, we compared RAS and MYC status in HI-LAPC-4 and PC-3 (both prostate cancer) cells with normal fibroblasts, and found increased expression of both proteins in the cancer cell lines (Suppl Fig 9) . The data are consistent with previous reports of increased MYC and RAS expression in solid tumor cells (34) , and suggest a selective effect of DPS on cancer cells via oncogenic pathways. Table 4E 
Connectivity Map analysis (Suppl
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Discussion
Resistance of many solid tumors to currently available cancer therapies is an important clinical problem, and is determined in part by the presence of hypoxia in the tumor microenvironment. In this study, we report that DPS effectively inhibited the growth of a variety of tumor cell lines in vitro under hypoxia and in vivo in xenograft tumor models.
Importantly, DPS significantly radiosensitized tumor cells in vitro under hypoxia and in vivo with a clinically relevant fractionated radiation regimen, but did not enhance the sensitivity of normal radiosensitive intestine and bone marrow to radiation. In fact, DPS actually radioprotected the GI epithelium, suggesting that DPS has the potential to significantly enhance the therapeutic index of radiation therapy. With higher cytotoxic and radiosensitizing potency under hypoxia than ATO, and a more favorable toxicity profile, DPS is more promising for the treatment of solid tumors. Although DPS, a dimethylarsenic conjugated to glutathione, may be generated as an intermediate in the 
